SEC Comment Letter for Coherus Oncology, Inc. (CHRS) (CIK 0001512762) (CHRS) — Nov 18, 2019

Coherus Oncology, Inc. (CHRS) (CIK 0001512762)
Date: Nov. 18, 2019 · CIK: 0001512762 · Accession: 0000000000-19-015589

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

November 18, 2019

Author

Jean-Frédéric Viret

Form

UPLOAD

Company

Coherus Oncology, Inc. (CHRS) (CIK 0001512762)

Letter

November 18, 2019 Jean-Frédéric Viret Chief Financial Officer Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, California 94065 Re:Coherus BioSciences, Inc. Form 10-K for the Fiscal Year Ended December 31, 2018 Filed February 28, 2019 Dear Mr. Viret: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

November 18, 2019
Jean-Frédéric Viret
Chief Financial Officer
Coherus BioSciences, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City, California 94065
Re:Coherus BioSciences, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2018
Filed February 28, 2019
Dear Mr. Viret:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io